Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Qeios ; 2022.
Article in English | EuropePMC | ID: covidwho-2254180

ABSTRACT

There have been reports of neurodegenerative diseases including Parkinsonism, Alzheimer's disease and Creutzfeldt Jakob disease following COVID-19. The exact pathogenesis of these has not been elucidated yet though authors have proposed the possibility of the hyper-inflammatory state of COVID-19 acting as a trigger through cytokine-induced inflammatory response of brain microglia and astrocytes, as well as damage resulting from the central nervous system hypoxia of severe COVID-19, or even the direct pathogenetic actions of SARS-CoV-2 on the brain. There have also been reports of worsening of Parkinsonian symptoms, new onset movement disorders and even rapidly progressive dementia following COVID-19 vaccination using different vaccine types. The occurrence of protein-aggregation mediated neurodegenerative syndromes following both COVID-19 and vaccination led us to explore the common thread of the Spike (S) protein as a potential mediator. In the current study, we investigated the interactions of S protein of SARS-CoV-2 with α-synuclein.

3.
Expert Rev Anti Infect Ther ; 19(10): 1245-1258, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1142581

ABSTRACT

Introduction: COVID-19 pandemic has caused huge loss of human lives and extensive socio-economic damages. The immuno-pathology of this disease is neither clearly understood nor there are effective drugs for severe cases of COVID-19. Repurposing of available drugs for the treatment of COVID-19 is imperative.Areas Covered: This review has gathered the evidence from PubMed, Google Scholar, WHO, and other reliable websites on COVID-19 and summarized the existing knowledge of the immuno-pathology of COVID-19. We elucidated how vitamin D through its diverse actions on immune effector cells, epithelial cells, or renin-angiotensin-aldosterone system could have a modulatory role on the pathogenic mechanisms of COVID-19. The epidemiological evidence associating vitamin D deficiency with the severity and incidence of COVID-19 is also presented. However, the evidence of clinical benefit to patients of COVID-19 from randomized controlled trials with vitamin D has not come as yet.Expert opinion: It is now established that fatality of COVID-19 is primarily determined by hyperactivation of the host's innate immune system in response to SARS-CoV-2 invasion, and thus the research on the immuno-modulatory and other roles of vitamin D against viral infections should be pursued vigorously. This would be also useful for future pandemics caused by other novel viruses.


Subject(s)
COVID-19/immunology , COVID-19/pathology , SARS-CoV-2/immunology , Vitamin D/immunology , Vitamin D/pharmacology , Angiotensin-Converting Enzyme 2/metabolism , COVID-19/epidemiology , Comorbidity , Humans , Immunity, Innate , Immunomodulation/drug effects , Renin-Angiotensin System/drug effects , SARS-CoV-2/physiology , Severity of Illness Index , Virus Replication , Vitamin D/therapeutic use , Vitamin D Deficiency/epidemiology , COVID-19 Drug Treatment
4.
Mult Scler Relat Disord ; 51: 102917, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1142159

ABSTRACT

BACKGROUND: Spinal cord complications associated with coronavirus infectious disease of 2019 (COVID-19) are being widely reported. The purpose of this systematic review was to summarize so far available pieces of evidence documenting de novo novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) mediated spinal cord demyelinating diseases. Indeed, the spinal demyelinating disorders that have been reported in those patients who have suffered from COVID-19 rather than on the people already living with diagnosed or undiagnosed primary demyelinating disorders. METHODS: We used the existing PRISMA consensus statement. Data were collected from PubMed, NIH Litcovid, EMBASE and Cochrane library databases, as well as Pre-print servers (medRxiv, bioRxiv, and pre-preints.org), until September 10, 2020, using pre-specified searching strategies. RESULTS: The 21 selected articles were all case reports and included 11 (52%) men and 10 (48%) women. The mean age was of 46.7 ±â€¯18.0. The neurological manifestations included weakness, sensory deficit, autonomic dysfunction and ataxia. In most cases, elevated cerebrospinal fluid protein as well as lymphocytic pleocytosis were found. SARS-CoV-2 was detected in five (24%) patients, meanwhile in 13 (62%) patients, the testing was negative. Testing was not performed in two cases and, in one, data were unavailable. Nearly half of the cases (N = 9) were associated with isolated long extensive transverse myelitis (LETM), whereas a combination of both LETM and patchy involvement was found in two. Only five patients had isolated short segment involvement and two patchy involvement. Furthermore, concomitant demyelination of both brain and spine was reported in six patients. Concerning the prognosis, most of the patients improved and the mortality rate was low (N = 2, <10%). CONCLUSION: Spinal cord demyelination should be added to the plethora of immune mediated neurologic complications associated with COVID-19.


Subject(s)
COVID-19 , Communicable Diseases , Nervous System Diseases , Female , Humans , Male , SARS-CoV-2 , Spinal Cord
5.
J Neurovirol ; 27(1): 12-25, 2021 02.
Article in English | MEDLINE | ID: covidwho-996484

ABSTRACT

With the growing number of COVID-19 cases in recent times. significant set of patients with extra pulmonary symptoms has been reported worldwide. Here we venture out to summarize the clinical profile, investigations, and radiological findings among patients with SARS-CoV-2-associated meningoencephalitis in the form of a systemic review. This review was carried out based on the existing PRISMA (Preferred Report for Systematic Review and Meta analyses) consensus statement. The data for this review was collected from four databases: Pubmed/Medline, NIH Litcovid, Embase, and Cochrane library and Preprint servers up till 30 June 2020. Search strategy comprised of a range of keywords from relevant medical subject headings which includes "SARS-COV-2," "COVID-19," and "meningoencephalitis." All peer reviewed, case-control, case report, pre print articles satisfying our inclusion criteria were involved in the study. Quantitative data was expressed in mean ± SD, while the qualitative date in percentages. Paired t test was used for analysing the data based on differences between mean and respective values with a p < 0.05 considered to be statistically significant. A total of 61 cases were included from 25 studies after screening from databases and preprint servers, out of which 54 of them had completed investigation profile and were included in the final analysis. Clinical, laboratory findings, neuroimaging abnormalities, and EEG findings were analyzed in detail. This present review summarizes the available evidences related to the occurrence of meningoencephalitis in COVID-19.


Subject(s)
COVID-19/physiopathology , Cough/physiopathology , Fatigue/physiopathology , Fever/physiopathology , Meningoencephalitis/physiopathology , SARS-CoV-2/pathogenicity , Adult , Aged , Antiviral Agents/therapeutic use , Azithromycin/therapeutic use , COVID-19/diagnostic imaging , COVID-19/virology , Confusion/diagnostic imaging , Confusion/drug therapy , Confusion/physiopathology , Confusion/virology , Cough/diagnostic imaging , Cough/drug therapy , Cough/virology , Dyspnea/diagnostic imaging , Dyspnea/drug therapy , Dyspnea/physiopathology , Dyspnea/virology , Electroencephalography , Fatigue/diagnostic imaging , Fatigue/drug therapy , Fatigue/virology , Female , Fever/diagnostic imaging , Fever/drug therapy , Fever/virology , Humans , Hydroxychloroquine/therapeutic use , Male , Meningoencephalitis/diagnostic imaging , Meningoencephalitis/drug therapy , Meningoencephalitis/virology , Middle Aged , Neuroimaging , SARS-CoV-2/drug effects , COVID-19 Drug Treatment
6.
Aging Dis ; 11(3): 480-488, 2020 May.
Article in English | MEDLINE | ID: covidwho-459276

ABSTRACT

The ongoing Corona virus (COVID-19) pandemic has witnessed global political responses of unimaginable proportions. Many nations have implemented lockdowns that involve mandating citizens not to leave their residences for non-essential work. The Indian government has taken appropriate and commendable steps to curtail the community spread of COVID-19. While this may be extremely beneficial, this perspective discusses the other reasons why COVID-19 may have a lesser impact on India. We analyze the current pattern of SARS-CoV-2 transmission, testing, and mortality in India with an emphasis on the importance of mortality as a marker of the clinical relevance of COVID-19 disease. We also analyze the environmental and biological factors which may lessen the impact of COVID-19 in India. The importance of cross-immunity, innate immune responses, ACE polymorphism, and viral genetic mutations are discussed.

SELECTION OF CITATIONS
SEARCH DETAIL